# This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Study · id `cardio:ct-nct03448419` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03448419](<https://clinicaltrials.gov/study/NCT03448419>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03448419

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

## Technical summary

Registry record NCT03448419. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-09-30 (actual). Results posted on 2020-10-22.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 312 participants (enrolled count; ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Started: 2018-03-20 (actual) (ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Primary completion: 2019-09-30 (actual) (ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Completion: 2019-10-07 (actual) (ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Results first posted: 2020-10-22 (ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Germany; Greece; Italy; Norway; Poland; Portugal; Spain; Sweden (ClinicalTrials.gov record NCT03448419, source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03448419-2020-11-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
- Condition: Heart Failure
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 676013f2d9706b837923ed6d6052a0e9b6bbc354d1c6ad318fffa1c29a5496bb
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
